Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Howard Colman

Neurology | Neurosurgery
Intermountain Health
Multidisciplinary Cancer Clinic - Huntsman Cancer Center
5121 South Cottonwood Street, Floor 3, 
Murray, UT 
Accepting New Patients
Offers Telehealth
29 Years of Experience
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Intermountain Health
Multidisciplinary Cancer Clinic - Huntsman Cancer Center
5121 South Cottonwood Street, Floor 3, 
Murray, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Howard Colman is a Neurologist and a Neurosurgery provider in Murray, Utah. Dr. Colman has been practicing medicine for over 29 years and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor. Dr. Colman is currently accepting new patients.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Washington University School Of Medicine, 1997
Residency
Barnes-Jewish Hospital
Specialties
Neurology
Neurosurgery
Licenses
Psychiatry & Neurology in UT
Board Certifications
American Board Of Psychiatry And Neurology
Fellowships
University of Texas MD Anderson Cancer Center
Hospital Affiliations
Intermountain Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Multidisciplinary Cancer Clinic - Huntsman Cancer Center
5121 South Cottonwood Street, Floor 3, Murray, UT 84107
Call: 801-507-3900
Other Locations
University of Utah - Department of NeuroSurgery
175 North Medical Drive East, Salt Lake City, UT 84112
Call: 801-585-7575
Huntsman Cancer Institute
1950 Circle Of Hope Drive, Salt Lake City, UT 84112
Call: 801-581-2121

Additional Areas of Focus

Dr. Colman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
View 10 Less Clinical Trials

115 Total Publications

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
View All 115 Publications
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Randy L. Jensen
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Randy L. Jensen
Neurosurgery

University Of Utah Clinical Neurosciences Center

175 North Medical Drive East, 
Salt Lake City, UT 
 (7.9 miles away)
801-585-7575
Experience:
28+ years
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients

Randy Jensen is a Neurosurgery provider in Salt Lake City, Utah. Dr. Jensen has been practicing medicine for over 28 years and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Radiation Induced Meningioma, Meningioma, and Awake Craniotomy. Dr. Jensen is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Rachna Malani
Neurology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Rachna Malani
Neurology

University Of Utah Acuity Care Services

50 N Medical Dr, 
Salt Lake City, UT 
 (8.4 miles away)
801-581-2121
Languages Spoken:
English, Sindhi
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachna Malani is a Neurologist in Salt Lake City, Utah. Dr. Malani is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Primary Lymphoma of the Brain, and Brain Tumor. Dr. Malani is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Peter H. Maughan
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Peter H. Maughan
Neurosurgery

Neurosurgical Associates - Murray

5171 South Cottonwood Street, Suite 950, 
Murray, UT 
 (0.1 miles away)
801-507-9555
Experience:
24+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Peter Maughan is a Neurosurgery provider in Murray, Utah. Dr. Maughan has been practicing medicine for over 24 years and is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Delirium, Awake Craniotomy, and Laminectomy. Dr. Maughan is currently accepting new patients.

VIEW MORE PRIMITIVE NEUROECTODERMAL TUMOR (PNET) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Colman's expertise for a condition
ConditionClose
  • Elite
  • Astrocytoma
    Dr. Colman is
    Elite
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Brain Tumor
    Dr. Colman is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Glioblastoma
    Dr. Colman is
    Elite
    . Learn about Glioblastoma.
    See more Glioblastoma experts
  • Glioma
    Dr. Colman is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Gliomatosis Cerebri
    Dr. Colman is
    Elite
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Gliosarcoma
    Dr. Colman is
    Elite
    . Learn about Gliosarcoma.
    See more Gliosarcoma experts
  • Distinguished
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Colman is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Colman is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Colman is
    Distinguished
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Medulloblastoma
    Dr. Colman is
    Distinguished
    . Learn about Medulloblastoma.
    See more Medulloblastoma experts
  • Metastatic Brain Tumor
    Dr. Colman is
    Distinguished
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Neuroepithelioma
    Dr. Colman is
    Distinguished
    . Learn about Neuroepithelioma.
    See more Neuroepithelioma experts
View All 10 Distinguished Conditions
  • Advanced
  • Cerebral Ventricle Cancer
    Dr. Colman is
    Advanced
    . Learn about Cerebral Ventricle Cancer.
    See more Cerebral Ventricle Cancer experts
  • Choroid Plexus Papilloma
    Dr. Colman is
    Advanced
    . Learn about Choroid Plexus Papilloma.
    See more Choroid Plexus Papilloma experts
  • Diffuse Midline Glioma H3 K27M-Mutant
    Dr. Colman is
    Advanced
    . Learn about Diffuse Midline Glioma H3 K27M-Mutant.
    See more Diffuse Midline Glioma H3 K27M-Mutant experts
  • Meningioma
    Dr. Colman is
    Advanced
    . Learn about Meningioma.
    See more Meningioma experts
  • Pineoblastoma
    Dr. Colman is
    Advanced
    . Learn about Pineoblastoma.
    See more Pineoblastoma experts
  • Radiation Induced Meningioma
    Dr. Colman is
    Advanced
    . Learn about Radiation Induced Meningioma.
    See more Radiation Induced Meningioma experts
View All 7 Advanced Conditions
  • Experienced
  • Acoustic Neuroma
    Dr. Colman is
    Experienced
    . Learn about Acoustic Neuroma.
    See more Acoustic Neuroma experts
  • Brain Stem Cancer
    Dr. Colman is
    Experienced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
  • Cerebrospinal Fluid Leak
    Dr. Colman is
    Experienced
    . Learn about Cerebrospinal Fluid Leak.
    See more Cerebrospinal Fluid Leak experts
  • Dysembryoplastic Neuroepithelial Tumors (DNET)
    Dr. Colman is
    Experienced
    . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
    See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
  • Hemangioblastoma
    Dr. Colman is
    Experienced
    . Learn about Hemangioblastoma.
    See more Hemangioblastoma experts
  • Schwannoma
    Dr. Colman is
    Experienced
    . Learn about Schwannoma.
    See more Schwannoma experts
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.